Fig. 1From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for ScotlandSchematic diagram of partitioned survival model used in the analysisBack to article page